A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Trial details
- Registry ID
- NCT06680258
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic TherapyNCT06680258 | Tempest Therapeutics | Phase 3 | Not yet recruiting | 2028-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |